Archive for the ‘Regenerative Medicine’ Category

Byrd Aesthetic and Anti Aging Coolsculpting Commercial
http://www.byrdaesthetic.com CoolSculpting trade; is cleared by the FDA for the non-invasive reduction of fat. This procedure is a clinically proven method for the selective reduction of body fat. The unwanted fat cells are gently cooled inducing a natural, controlled elimination. Results are permanent. Dr. Marcia Byrd of the Byrd Aesthetic and Anti-Aging Center is located in Atlanta, Georgia. She is board-certified by the American Board of Laser Surgery and the American Board of Anti-Aging and Regenerative Medicine. For more information about CoolSculpting trade; and losing unwanted fat, call Dr. Byrd #39;s office toll free at 1.866.671.5633.From:byrdaestheticcenterViews:0 0ratingsTime:00:31More inPeople Blogs

See the rest here:
Byrd Aesthetic and Anti Aging Coolsculpting Commercial - Video

Regenerative Medicine Lecture and Discussion with Students
The first presentation of the fall 2012 Topics in Regenerative Medicine lecture series featured Dr. John Warner who discussed his research on the development of new treatment approaches for life-threatening diseases. Dr. Warner, Scientific Director of Clinical Research/Stem Cell Institute at the University of Minnesota is internationally recognized as an expert in stem cells and umbilical cord blood transplantation.From:SacStateVideoViews:2 0ratingsTime:02:15More inEducation

Read more here:
Regenerative Medicine Lecture and Discussion with Students - Video

Can Growth Hormone (HGH) Treat Fibromyalgia?
MetroMD.net Human Growth Hormone (HGH) Replacement is a popular therapy that is effective in reversing the signs and symptoms of aging. But HGH is also very effective in treating the ill effects of fibromyalgia. Dr. Martin discusses the treatment in this brief video presentation. For more info, visit us at MetroMD.net or call (323) 285-5300. The MetroMD Institute of Regenerative Medicine is located in Hollywood at the heart of Los Angeles.From:MetroMDViews:1 0ratingsTime:01:37More inScience Technology

Link:
Can Growth Hormone (HGH) Treat Fibromyalgia? - Video

AABB Center for Cellular Therapies
AABB Chief Executive Officer Karen L. Shoos, JD, describing the role of the newly created AABB Center for Cellular Therapies in supporting responsible innovation in the cellular therapy and regenerative medicine field.From:aabbmediaViews:8 0ratingsTime:02:30More inNonprofits Activism

Here is the original post:
AABB Center for Cellular Therapies - Video

Egan Wellness Anti Aging Skin Care Spa Video | Spa in Covington
my.datasphere.com Egan Wellness Skin Care Spa! The best in primary care, preventative medicine and aesthetic services! Pamela Egan, Nurse Practitioner has completed a Fellowship with the American Academy of Anti-Aging Regenerative Medicine. We are focused on providing high-quality service and customer satisfaction - we will do everything we can to meet your expectations. Our company is based on the belief that our customers #39; needs are of the utmost importance. Our entire team is committed to meeting those needs. As a result, a high percentage of our business is from repeat clients and referrals. Look Good Feel good with Evidenced-based conventional and natural methods including "Natural Hormone Replacement, Metabolic, and Nutritional Medicine" for men women. We also offer a full complement of skin treatments including Venus Freeze, designer facials, chemical peels, Botox Fillers. Whether you #39;re looking to obtain optimum health or to pamper yourself, the professionals at Egan Wellness Skin Care Spa are eager to meet all of your needs. Give us a call at (985) 892-3031 to schedule your appointment or visit us at http://www.pamelaegan.com to learn more about the services we offer. 12545376 Facials, Microdermabrasion, LED Light Therapy, Lipolysis, Collagen and Elastic Restructuring, Syneron Auroro IPL, Prestige Peel (Mid Depth), Brilliance Peel, Venus Freeze, Covington, WWLFrom:DataSphereVideosViews:1 1ratingsTime:01:17More inPeople Blogs

Read the original:
Egan Wellness Anti Aging

Making It Cool: Gen Z Meets Manufacturing
Aspiring roboticists are seeking to change the way we live, work, play and fight wars through artificial intelligence; 3D printing has taken college classrooms by storm allowing art students to create mold models once reserved for technical professionals, and students in institutes of regenerative medicine are actually manufacturing organs for humans and animals. So what makes manufacturing cool? How do we get today #39;s youth excited about new opportunities in manufacturing? Listen to our live broadcast as our panelists talk about making manufacturing cool. Panelists: Chris Anderson, Editor of Wired Magazine and CEO of 3D Robotics Adam Friedman, Director of the Pratt Center for Community Development Aly Khalifa, President at Gamil Design, Inc. Joe LaRussa, Director of Membership at Society of Manufacturing Engineers AJ Sweatt, Principal at AJ Sweatt Logic CommunicationsFrom:Anita Brown-GrahamViews:0 0ratingsTime:59:34More inNews Politics

See more here:
Making It Cool: Gen Z Meets Manufacturing - Video

Tissue Engineering And Regenerative Medicine: Advancing Toward Clinical Therapies : Chapter 1 From T
ll4.me Tissue Engineering And Regenerative Medicine: Advancing Toward Clinical Therapies : Chapter 1 From Transitional Approaches In Tissue Engineering Reg Chapter 1 from Translational Approaches in Tissue Engineering and Regenerative Medicine,Jeremy J. Mao, Gordana Vunjak-Novakovic, Antonios G. Mikos, Anthony Atala, Editors Publisher: Artech House Publishers Illustration: N Language: ENG Title: Tissue Engineering and Regenerative Medicine: Advancing Toward Clinical Therapies : Chapter 1 from Transitional Approaches in Tissue Engineering Reg Pages: 00000 (Encrypted PDF) On Sale: 2007-11-30 SKU-13/ISBN: 9781607832362 Category: Technology Engineering : General Chapter 1 from Translational Approaches in Tissue Engineering and Regenerative Medicine,Jeremy J. Mao, Gordana Vunjak-Novakovic, Antonios G. Mikos, Anthony Atala, Editors Publisher: Artech House Publ technology, engineering, generalFrom:shirleymiller364Views:0 0ratingsTime:00:14More inPeople Blogs

Read the original post:
Tissue Engineering And Regenerative Medicine: Advancing Toward Clinical Therapies : Chapter 1 From T - Video

Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine"
The good part about getting older is that we gain some wisdom and patience. The bad part is that our bodies start to wear out. But what if we could revitalize our damaged bits back to a healthy state? Come hear what the field of Regenerative Medicine is striving to achieve, and learn how it all begins with the stem cell. Jill Helms is a professor in Plastic and Reconstructive Surgery in the department of surgery at Stanford University #39;s School of Medicine. This Classes Without Quizzes lecture was filmed on location at Stanford Reunion Homecoming 2012 by the Stanford Alumni Association.From:StanfordAlumniViews:11 0ratingsTime:54:05More inEducation

Excerpt from:
Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine" - Video

cryocell | Why Store Your Cord Blood In a Bank?
http://www.cordbloodrecommendation.com A large number of people die waiting for a transplant due to this reason. Before any blood donations are made it is important for a pregnant mother interested to make the donation to contact the bank before the thirty fourth week of her pregnancy. However, private banking is generally not recommended unless there is a family history of specific genetic diseases. It contains stem cells that have been found to be excellent for research and treatment of many diseases. A man can change his god-gifted features wishfully with the help of science. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. One study in particular by Wagner, et al. ""Settling on a name for your newborn is definitely something all parents spend time doing, but one decision that is rarely thought of or overlooked is saving your newborn #39;s cord blood. The mother will be informed about the status of the blood unit and the test results so that she is aware of any infection or disease that might affect her baby. Many parents see placental and cord blood banking as valuable tools to help them secure potentially lifesaving treatment options their families may some day ...From:loshoteles enmedellinViews:1 0ratingsTime:01:18More inScience Technology

Read the original here:
cryocell | Why Store Your Cord Blood In a Bank? - Video

Will Human Growth Hormone (HGH) Affect Fertility?
MetroMD.net Human Growth Hormone (HGH) Replacement is a popular therapy that is effective in reversing the signs and symptoms of aging. Among it #39;s many benefits, HGH increases libido in many patients. But we are often asked about HGH #39;s effect on fertility for both men and women. Dr. Martin addresses these concerns in this brief video presentation. For more info, visit us at http or call (323) 285-5300. The MetroMD Institute of Regenerative Medicine is located in Hollywood at the heart of Los Angeles.From:MetroMDViews:3 0ratingsTime:02:09More inScience Technology

More:
Will Human Growth Hormone (HGH) Affect Fertility? - Video

Improve Your Cholesterol with Human Growth Hormone (HGH)
MetroMD.net Did you know that you can improve your cholesterol with HGH? Human Growth Hormone Replacement is a popular therapy that is effective in reversing the signs and symptoms of aging. One of the lesser-known benefits is that HGH can actually improve your blood profile and reduce the risk of heart disease. Dr. Alex Martin MD explains how and why in this brief video presentation. For more info, visit us at MetroMD.net or call (323) 285-5300. The MetroMD Institute of Regenerative Medicine is located in Hollywood at the heart of Los Angeles.From:MetroMDViews:0 0ratingsTime:01:54More inScience Technology

Read more:
Improve Your Cholesterol with Human Growth Hormone (HGH) - Video

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and year-to-date period ended September 30, 2012 and highlighted recent corporate accomplishments.

Financial Results

Net Loss

Net loss attributable to BioTime for the third quarter of 2012 was $5.0 million or $0.10 per share, compared to a net loss of $3.7 million or $0.08 per share for the same period of 2011. For the nine months ended September 30, 2012, net loss attributable to BioTime was $15.4 million, or $0.31 per share, compared to $11.2 million, or $0.23 per share for the same period of 2011.

Revenue

Total revenue, on a consolidated basis, was approximately $1.0 million and $2.7 million for the third quarter and year-to-date period ended September 30, 2012, respectively, compared to $1.2 million and $2.8 million for the same periods of 2011. Total revenue was effectively the same as prior periods, but license revenue increased based upon our subsidiary LifeMap Sciences subscription and advertising revenue for GeneCards, which was offset by lower grant revenue recognized due to the completion of the California Institute of Regenerative Medicine (CIRM) grant in August 2012.

Expenses

Total operating expenses for the third quarter of 2012 were $6.8 million, compared to $5.4 million for the comparable period in 2011. Research and development expenses for the second quarter of 2012 were $4.6 million, compared to $3.5 million for the comparable 2011 period. General and administrative expenses for the third quarter of 2012 were $2.2 million, compared to $1.9 million for the comparable 2011 period.

Total operating expenses for the first nine months of 2012 were $20.4 million, compared to $15.9 million for the comparable period in 2011. Research and development expenses for the first nine months of 2012 were $13.3 million, compared to $9.8 million for the comparable 2011 period. General and administrative expenses for the first nine months of 2012 were $7.0 million, compared to $6.2 million for the comparable 2011 period.

More:
BioTime Announces Third Quarter 2012 Financial Results and Recent Corporate Accomplishments

By Jeff Hansel The Post-Bulletin, Rochester MN

Even as regenerative medicine emerges as a new hope for many, doctors caution that it takes time to get a new discovery from the research lab to patient treatment.

As an example, one type of regenerative medicine, treatment of blood cancer disorders, has taken about 50 years to develop, said Mayo Clinic heart specialist Dr. Andre Terzic,director of Mayo's regenerative medicine center.

"We want to make sure that we are not creating a hype in the society but that we are really offering hope for patients, and ultimately definitive solutions," he said.

Yet it might be hard for people awaiting cures to contain their excitement.

"It has clearly gone from science fiction into rigorous science, and now from science it's going into practice," Terzic said. "It's not yet a broadly-offered servicebut it's in the phase of rigorous clinical trials."

Dr. Stephen Russell, Mayo Clinic's associate director for translation, says"we can't just take what we did in the mouse and apply it in the clinic."

"What we have to do is we have to develop a clinical protocol, we have to scale up the manufacture of the product that we're going to use, which may involve the scaled culturing of cells from a patient," he said.

Human research studies must pass muster from the Institutional Review Board at Mayo as well as from the FDA.

"That process with your foot hard on the accelerator is probably a two- to three-year process," Russell said.

View original post here:
Regenerative medicine raises hope

Keynote Speaker: Daniel Kraft bull; Presented by SPEAK Inc.
Stanford and Harvard Trained Physician-Scientist, Inventor, Entrepreneur and Innovator Dr. Daniel Kraft has over 20 years of experience in clinical practice, biomedical research and healthcare innovation. Daniel chairs the Medicine track for Singularity University and is Executive Director for FutureMed, a program which explores convergent, exponentially developing technologies and their potential in biomedicine and healthcare. Following undergraduate degrees at Brown and medical school at Stanford, Dr. Kraft was board certified in the Harvard combined Internal Medicine and Pediatrics residency program at the Massachusetts General Hospital and Boston Children`s Hospital. He went on to complete Stanford fellowships in hematology/oncology bone marrow transplantation, and extensive research in stem cell biology and regenerative medicine. He has multiple scientific publications (including in Nature and Science), medical device, immunology and stem cell related patents through faculty positions with Stanford University School of Medicine and as clinical faculty for the pediatric bone marrow transplantation service at UCSF. Dr. Kraft recently founded IntelliMedicine, focused on enabling connected, data driven, and integrated personalized medicine. He is also the inventor of the MarrowMiner, an FDA approved device for the minimally invasive harvest of bone marrow, and founded RegenMed Systems, a company developing technologies to enable adult stem cell based regenerative ...From:speakincViews:0 0ratingsTime:14:53More inPeople Blogs

See the original post:
Keynote Speaker: Daniel Kraft • Presented by SPEAK Inc. - Video

Integrating History And Philosophy Of Science
ll4.me Integrating History And Philosophy Of Science From the contents: Introduction by Seymour Mauskopf and Tad Schmaltz Part I: General Reflections Thomas Kuhn and Interdisciplinary Conversation: Why Historians and Philosophers of Science Stopped Talking to One Another , Jan Golinski The History and Philosophy of Science History, David M. Miller What in Truth Divides Historians and Philosophers of Science?, Kenneth Caneva History and Philosophy of Science: Recollections and Reflections, Ronald Giere Philosophy of Science and Its Historical Reconstructions , Peter Dear The Underdetermination Debate: How Lack of History Leads to Bad Philosophy, Wolfgang Pietsch Part II: Case Studies Beyond Case Studies: History as Philosophy, Hasok Chang Hidden Entities and Experimental Practice: Renewing the Dialogue between History and Philosophy of Science, Theodore Arabatzis Studying Methodological Thought: S. Weir Mitchell s Research on the Venom of Poisonous Snake, Jutta Schickore Quantum Gravity: History, Historiography and Philosophy, Dean Rickles Social Epistemology of Stem Cell Research: History, Philosophy and Experiment, Melinda Fagan History and Philosophy of Science at Work: Making Regenerative Medicine Better EAN/ISBN : 9789400717459 Publisher(s): Springer, Berlin, Springer Netherlands Discussed keywords: Geschichtsschreibung, Interdisziplinaritt, Wissenschaftsphilosophie Format: ePub/PDF Author(s): Mauskopf, Seymour - Schmaltz, Tad From the contents: Introduction by ...From:susanbranch9865Views:0 0ratingsTime:00:16More inPeople Blogs

Excerpt from:
Integrating History And Philosophy Of Science - Video

CombiCult Workflow
A overview on how Plasticell (www.plasticell.co.uk) uses combinatorial cell culture (CombiCult) to discover optimised stem cell differentiation protocols in record time, at a fraction of the cost of the status quo while reducing project return risk. CombiCult is used by our customers in a range of applications in regenerative medicine, cell therapy and research and development.From:PlasticellLimitedViews:0 0ratingsTime:06:40More inScience Technology

See the article here:
CombiCult® Workflow - Video

Vetrix
Overview of Vetrix, a veterinary regenerative medicine company.From:ReThinkHealingViews:1 0ratingsTime:01:40More inScience Technology

Follow this link:
Vetrix - Video

AFIRM Wake Forest-Pittsburgh Consortium Research
The AFIRM #39;s success to date can be ascribed, at least in part, to the program #39;s emphasis on establishing partnerships and collaborations. Funding for the AFIRM is a six-way partnership among the US Army, Navy, and Air Force; the Veterans Health Administration; the Defense Health Program; and the National Institutes of Health. Research under the AFIRM is conducted through two independent research consortia working with the US Army Institute of Surgical Research (USAISR). One research consortium is led by Rutgers, the State University of New Jersey, and the Cleveland Clinic (RCCC [Rutgers-Cleveland Clinic Consortium]) while the other is led by Wake Forest University Baptist Medical Center and the McGowan Institute for Regenerative Medicine in Pittsburgh (WFPC [Wake Forest-Pittsburgh Consortium]). This video discusses some of the research taking place at the WFPC.From:USAMMDAViews:0 0ratingsTime:05:55More inEducation

Here is the original post:
AFIRM Wake Forest-Pittsburgh Consortium Research - Video

stem cell banking | Knowing More About Cord Blood Banking
http://www.cordbloodrecommendation.com The umbilical cord blood is rich in stem cells as the baby #39;s organs, tissues and body is developed by it. Diseases that are genetically based would most likely be an allogenic transplant. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. There is also another option given by non-profit cord blood banks, of free programs through which one can store umbilical cord blood stem cell samples. A man can change his god-gifted features wishfully with the help of science. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. One study in particular by Wagner, et al. ""The theory exists that any reduction in the volume of umbilical cord blood units in albumin or dextran prior to transfusing into patients leads to better cell viability. The mother will be informed about the status of the blood unit and the test results so that she is aware of any infection or disease that might affect her baby. Many parents see placental and cord blood banking as valuable tools to help them secure potentially ...From:fivespanishViews:0 0ratingsTime:01:18More inScience Technology

Excerpt from:
stem cell banking | Knowing More About Cord Blood Banking - Video

PHILADELPHIA As researchers work on reconfiguring cells to take on new regenerative properties, a new review from Penn Medicine plastic surgeons sheds additional light on the potential power of adipose-derived stem cells - or adult stem cells harvested from fatty tissue - in reconstructive and regenerative medicine.

Reconstructive plastic surgeons have clinically integrated "fat grafting" into different surgeries for years, for breast, facial, and other reconstructive and restorative surgeries, with good success. Now, researchers are beginning to understand the power that fatty tissue holds. This new paper, published in the Aesthetic Surgery Journal, enforces that adipose-derived stem cells can be routinely isolated from patients and, once molecular methods are worked out, may be useful for a multitude of regenerative medicine applications.

"The opportunities for regenerative medicine interventions based on adult stem cells are tremendous. It is critically important for us to better understand the biology of these cells so that we can develop novel, safe and effective treatments for our patients using their own cells." said the paper's senior author, Ivona Percec, MD, PhD, assistant professor in the division of Plastic Surgery in the Perelman School of Medicine at the University of Pennsylvania.

Many groups are looking into different modes of isolating and modifying these cells for their regenerative properties, including experts at Penn's Institute for Regenerative Medicine and around Penn Medicine. For example, Dr. Percec's team is conducting translational research into the mechanisms controlling adipose-derived stem cells, and how they contribute to the normal human aging process.

Stem cells can undergo multiple divisions without differentiation, making them useful tools for cell-replacement therapy. Embryonic stem cells can convert to any cell type, whereas adult stem cells, like the stem cells derived from fat, can differentiate into many, but not all, cell types. A person's own fat tissue could then potentially be converted into cells specially designed to repair damage to the heart, cartilage, blood vessels, brain, muscle, or bone.

As regenerative medicine techniques are refined, experts will continue to explore the utility and benefits of stem cells derived from adipose tissue.

The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.

Read the original:
Fat-derived Stem Cells Hold Potential for Regenerative Medicine

umbilical cord stem cells | Cord Blood Storage and Why
http://www.cordbloodrecommendation.com By preserving this cord blood through cord blood banking, your baby will be ensured a perfect source of cells in the event of some unfortunate accident, disease or other life threatening illness. Safety is a concern in the public banks because of the high cost of maintaining the storage unit. Besides this, children without siblings and people belonging to certain races or ethnicities, who don #39;t have access to other people of their race in their area, also face problems. Sources of stem cells, such as blood, fats, bone, or umbilical cords were simply named as sources, not as natural resources. By preserving your baby #39;s cord blood, you are actually saving your child from the dangers of waiting for matching donors during emergencies. ""Regenerative medicine is the next evolution of medical treatments. Stromal cells are a kind of cells that form bone, cartilage, fat, and fibrous connective tissue. There are people who are against this practice as well and there are many opinions supporting it too therefore it is best to consult your doctor regarding this issue and get the right advice. For this, the patient needs a donor whose tissues and cells match his own. In case the cord blood is collected before the removal of placenta, the umbilical cord is clamped and detached as usual. - Stem groups can be certainly obtained from cord blood- flex blood stem groups are a 100% reach for the patron, 50% reach for biological parents and 25% reach for blood ...From:Alexander santafeViews:0 0ratingsTime:01:13More inScience Technology

Continued here:
umbilical cord stem cells | Cord Blood Storage and Why - Video

Biodegradable Systems In Tissue Engineering And Regenerative Medicine
ll4.me Biodegradable Systems In Tissue Engineering And Regenerative Medicine The most important materials in development for use in tissue engineering, replacement, and regeneration are based on polymers and on composites reinforced with bioactive ceramics. The first book to address the topic in an integrated manner, Biodegradable Materials in Tissue Engineering presents an extensive description of biodegradable polymers used in medicine and explores their design, development, and processing. The authors discuss the performance of biodegradable systems and the special requirements that should be taken into account when evaluating their biocompatibility. Included are several methodologies for tailoring cell adhesion and proliferation on the surface of biodegradable polymers. Publisher: CRC Press Illustration: N Language: ENG Title: Biodegradable Systems in Tissue Engineering and Regenerative Medicine Pages: 00000 (Encrypted PDF) On Sale: 2004-11-24 SKU-13/ISBN: 9780849319365 Category: Science : GeneralWords: in replacement The most important materials in development for use in tissue engineering, replacement, and regeneration are based on polymers and on composites reinforced with bioactive ceramics. The first book to a science, generalFrom:robertarellano9865Views:0 0ratingsTime:00:11More inPeople Blogs

Continue reading here:
Biodegradable Systems In Tissue Engineering And Regenerative Medicine - Video

Pharma-Biotech Needs a New Financing Model or We Are Doomed!
Duane Roth, CEO, CONNECT Webinar Date: April 27, 2011 Agenda: What killed the fully integrated model? Has the start-up model run its course? What will the next model look like? Where will future investments come from? What role should federal and state government play? Speaker Biography: Duane J. Roth is Chief Executive Officer and Member of the Board of CONNECT. CONNECT is the globally recognized nonprofit organization dedicated to creating and sustaining the growth of innovative technology and life science businesses in San Diego. CONNECT has been directly involved with over 2000 companies since its inception in 1985 and these companies have secured over $10 billion in funding. Prior to joining CONNECT, Mr. Roth founded Alliance Pharmaceutical Corp., where he served as Chairman of the Board. Prior to Alliance, he held senior management positions at Johnson Johnson and Wyeth (now Pfizer) operating companies. He has served as a Member of the Board of Directors and executive committees of the Biotechnology Industry Organization (BIO), the California Healthcare Institute (CHI) and BIOCOM (past Chair). Mr. Roth was appointed to the oversight board of the California Institute of Regenerative Medicine (CIRM) by Governor Arnold Schwarzenegger in 2006 and was elected Vice Chairman in 2009.From:ShareVaultViews:0 0ratingsTime:53:57More inEducation

Read the original:
Pharma-Biotech Needs a New Financing Model or We Are Doomed! - Video

ALACHUA, Fla.--(BUSINESS WIRE)--

AxoGen, Inc. (AXGN), a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions, today announced revenues for the third quarter ended September 30, 2012 of $1.98 million, a 74% increase over revenues of $1.14 million in the third quarter 2011.

Compared to last year, we delivered solid top-line growth during the quarter despite cash constraints and the distraction of raising capital, commented Karen Zaderej, Chief Executive Officer of AxoGen. In addition, to remain in compliance with covenants imposed by our former lender, we carefully managed cash and chose to defer certain sales force growth and marketing activities.

Ms. Zaderej continued, As a result of the recent financing with PDL, we paid off all bank debt and eliminated the restrictive lender requirements. This will allow us the flexibility to develop and expand our sales force and invest in significant marketing efforts.

Revenues

Revenues for the period were $1.98 million, a 74% increase, compared to $1.14 million for the same period in 2011. These results were due to expansion of sales and marketing efforts versus third quarter 2011 and focused on the development of new accounts as well as penetration into key accounts.

Revenues decreased 1.5% compared to second quarter 2012 revenues of $2.01 million. This is the second year in which the third quarter has been relatively flat compared to the second quarter. While this may suggest seasonality in peripheral nerve surgery, it is important to note that in both of these quarters there were material corporate transactions that may have distracted operations. In addition, during the period, the Company made personnel changes in certain sales territories, but did not increase the size of its direct sales force.

Gross Profit

Gross profit for the period increased to $1.44 million from the reported third quarter 2011 results of $10,000. The favorable results reflect increased revenues and lower manufacturing cost in 2012 and exclude an inventory write-off of $0.83, which occurred during the third quarter 2011.

The gross profit margin for the period increased to 73% compared to 0.9% for the same quarter last year.

Read more:
AxoGen, Inc. Announces Third Quarter 2012 Financial Results

WINSTON-SALEM, N.C., Nov. 6, 2012 /PRNewswire/ --Tengion, Inc. (TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Tuesday, November 13, 2012, at 8:30 a.m. EST to provide a business update and discuss its third quarter 2012 financial results.

To participate in the call, please dial 866-800-8651 (domestic) or 617-614-2704 (international) and reference access code 64284960.

The conference call can be accessed from the Investors section of the Company's website at http://www.tengion.com or directly at http://www.media-server.com/m/p/6pr35s84. The webcast will also be archived on the website.

About TengionTengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

Originally posted here:
Tengion to Host Conference Call to Provide a Business Update and Report Third Quarter 2012 Financial Results on ...